Table 4.
Cost of Management per Year per Person and Cost‐Effectiveness Analysis (Healthcare Provider's Perspective)
| Cost | Dabigatran (n = 122) | Warfarin (n = 122) | P Value |
|---|---|---|---|
| Median total cost (25th, 75th percentile), US$ | 461 (341, 886) | 1306 (914, 2584) | <0.001a |
| Median clinic visit cost (25th, 75th percentile), US$ | 430 (321, 748) | 932 (602, 1727) | <0.001a |
| GOPCb | 0–212 | 0–85 | 0.191 |
| FMb | 0–622 | 0–802 | 0.576 |
| SOPC | 388 (292, 591) | 713 (491, 983) | <0.001a |
| A&Eb | 0–210 | 0–673 | 0.012c |
| Inpatientb | 0–14 323 | 0–40 617 | <0.001a |
| Median investigation cost (25th, 75th percentile), US$ | 16 (0, 57) | 325 (195, 526) | <0.001a |
| Laboratory test | 16 (0, 57) | 325 (195, 524) | <0.001a |
| Proceduresb | 0–1575 | 0–1579 | 0.995 |
| Treatment cost, US$b | 0–232 | 6–40 | <0.001a |
| Drug costb | 0 | 6–40 | <0.001a |
| Side effectsb | 0–232 | 0–21 | 0.071 |
| Cost‐effective analysis | |||
| ICER, US$ per cardiac event prevented | −34 350 (dabigatran dominant) | ||
| ICER, US$ per bleeding event prevented | −10 305 (dabigatran dominant) | ||
Abbreviations: A&E, accident and emergency; FM, family medicine; GOPC, general outpatient clinic; ICER, incremental cost‐effectiveness ratio; SOPC, specialist outpatient clinic.
a
P ≤ 0.01.
b
If the median, 25th percentile, and 75th percentile are all zero, the range is shown. c P < 0.05.